P

Inventor

NAIR JAYAPRAKASH K

US34 patents
⚠️ This page may combine multiple inventors who share the name “NAIR JAYAPRAKASH K”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ALNYLAM PHARMACEUTICALS INC

26 patents
US9682922B2Jun 20, 2017

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC39 citations94
US11504391B1Nov 22, 2022

Modified RNA agents with reduced off-target effect

ALNYLAM PHARMACEUTICALS INC18 citations84
US10995336B2May 4, 2021

Serpina1 iRNA compositions and methods of use thereof

ALNYLAM PHARMACEUTICALS INC8 citations83
US10808246B2Oct 20, 2020

Oligonucleotide-ligand conjugates and process for their preparation

ALNYLAM PHARMACEUTICALS INC6 citations83
US10086081B2Oct 2, 2018

Carbohydrate conjugated RNA agents and process for their preparation

ALNYLAM PHARMACEUTICALS INC11 citations83
US9566340B2Feb 14, 2017

Monomers and oligonucleotides comprising cycloaddition adduct(s)

ALNYLAM PHARMACEUTICALS INC11 citations83
US12364762B2Jul 22, 2025

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC0 citations73
US12350338B2Jul 8, 2025

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC0 citations73
US12343398B2Jul 1, 2025

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC0 citations73
US12239709B2Mar 4, 2025

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC0 citations73
US11666653B2Jun 6, 2023

Carbohydrate conjugates as delivery agents for oligonucleotides

ALNYLAM PHARMACEUTICALS INC1 citations73
US9701623B2Jul 11, 2017

Di-aliphatic substituted pegylated lipids

ALNYLAM PHARMACEUTICALS INC5 citations73
US11597932B2Mar 7, 2023

Chirally-enriched double-stranded RNA agents

ALNYLAM PHARMACEUTICALS INC3 citations70
US12059468B2Aug 13, 2024

Carbohydrate conjugates as delivery agents for oligonucleotides

ALNYLAM PHARMACEUTICALS INC0 citations63
US12275938B2Apr 15, 2025

Modified RNA agents with reduced off-target effect

ALNYLAM PHARMACEUTICALS INC0 citations62
US12247203B2Mar 11, 2025

Modified RNA agents with reduced off-target effect

ALNYLAM PHARMACEUTICALS INC0 citations62
US12221607B2Feb 11, 2025

Multi-targeted single entity conjugates

ALNYLAM PHARMACEUTICALS INC0 citations62
US12173288B2Dec 24, 2024

Oligonucleotide-ligand conjugates and process for their preparation

ALNYLAM PHARMACEUTICALS INC0 citations62
US11944687B2Apr 2, 2024

Carbohydrate conjugate RNA agents and process for their preparation

ALNYLAM PHARMACEUTICALS INC0 citations62
US11725207B2Aug 15, 2023

Serpina1 iRNA compositions and methods of use thereof

ALNYLAM PHARMACEUTICALS INC1 citations62
US11053495B2Jul 6, 2021

Multi-targeted single entity conjugates

ALNYLAM PHARMACEUTICALS INC0 citations62
US12397013B2Aug 26, 2025

Extrahepatic delivery

ALNYLAM PHARMACEUTICALS INC0 citations61
US12005074B2Jun 11, 2024

Extrahepatic delivery

ALNYLAM PHARMACEUTICALS INC0 citations61
US10266484B2Apr 23, 2019

Biodegradable lipids for the delivery of active agents

ALNYLAM PHARMACEUTICALS INC0 citations52
US10550386B2Feb 4, 2020

Monomers and oligonucleotides comprising cycloaddition adduct(s)

ALNYLAM PHARMACEUTICALS INC0 citations51
US11286482B2Mar 29, 2022

Endosomal cleavable linkers

ALNYLAM PHARMACEUTICALS INC0 citations46

ARBUTUS BIOPHARMA CORP

7 patents

RAJEEV KALLANTHOTTATHIL G

1 patent